Facts checked on 2 November 2026.
Mounjaro injection Eli Lilly ki dawa tirzepatide ka brand hai: hafte mein ek baar lagne wala prescription injection1,2. Tirzepatide do gut-hormone receptors, GIP aur GLP-1, ko activate karta hai3,4. India mein iske do upyog hain: type 2 diabetes, aur adults mein weight management5. PharmEasy ke mutabik Mounjaro Schedule H dawa hai, jo sirf doctor ke prescription par milti hai6. Bloomberg ke mutabik India mein koi generic tirzepatide nahi hai, aur tirzepatide abhi patent ke andar hai7.
India mein tirzepatide ke brand: Indian news reports, Bloomberg, Cipla ki stock-exchange filing aur PharmEasy ki 1 October 2026 ki listing ke anusaar1,6,7,8,9.
Facts checked on 2 November 2026.
| Brand | Company | Form aur strengths | India mein approved upyog (source) | India mein kab se |
|---|---|---|---|---|
| Mounjaro (tirzepatide) | Eli Lilly | KwikPen, ek pen mein 4 weekly doses: 2.5, 5, 7.5, 10, 12.5 aur 15 mg. Single-dose vial: 2.5 mg aur 5 mg | Type 2 diabetes; adults mein weight management, BMI 30 ya zyada, ya 27 ya zyada ke saath wajan se judi bimari (The Week / PTI) | 20 March 2025; KwikPen 15 August 20251,2,5,6 |
| Yurpeak (tirzepatide) | Cipla bechta hai; Lilly banata hai | Sirf KwikPen, ek pen mein chaar weekly doses; strengths 2.5, 5, 7.5, 10, 12.5 aur 15 mg | Mounjaro jaisa, BMI 30 ya 27 ki wahi shart (Cipla ki filing) | 11 December 20258,9,10 |
| Generic tirzepatide | Koi nahi | Koi nahi | Bloomberg (April 2026): India mein generic nahi, tirzepatide patent ke andar | Nahi7 |
Facts checked on 2 November 2026.
How this page was checked. Is page mein untees sources hain: Indian reports aur filings, CDSCO minutes, Indian sarkar ke pages, PharmEasy, US labels aur UK ki NHS. Saare facts 2 November 2026 ko check kiye gaye. Zelta ke kisi doctor ne abhi tak is page ko review nahi kiya hai.
Mounjaro kaise kaam karta hai: India mein hafte mein ek baar ka injection
UK ki NHS tirzepatide ko "dual agonist" kehti hai: yeh bhookh kam karta hai aur pet ko zyada der tak bhara mehsoos karata hai4. NHS ke mutabik GLP-1 dawaein khane ke baad pet ke khali hone ki speed dheemi karti hain11. US Mounjaro label ke mutabik tirzepatide ki half-life lagbhag 5 din hai, isliye ise hafte mein ek baar lagaya jata hai12.
India mein KwikPen launch par Lilly ne kaha ki pen CDSCO se approved hai2. US labels mein tirzepatide ki koi tablet nahi hai3,12. Semaglutide tablet ke liye semaglutide tablets ke upyog dekhein.
Mounjaro injection kis liye diya jata hai: India ke approved upyog
The Week mein chhapi PTI report ke anusaar India mein Mounjaro type 2 diabetes aur weight management ke liye launch hua5. Adults mein weight management ki shart: BMI 30 ya usse zyada, ya BMI 27 ya usse zyada aur wajan se judi koi bimari5. Cipla ki Yurpeak filing mein bhi yahi upyog aur yahi cut-off hain9.
June 2026 mein CDSCO ki expert committee ne kaha ki is BMI cut-off ko hatana theek nahi hai13. Kaaran: US aur Asian aabadi mein obesity aur overweight ki definition alag hai13. India sarkar ke ek backgrounder mein BMI 25 ya zyada obesity hai, aur 23.00 se 24.99 overweight14. Matlab koi vyakti Indian definition se obese ho sakta hai, phir bhi Mounjaro ke Indian upyog ki BMI shart se neeche reh sakta hai5,14.
Dose kaise badhti hai: India ke KwikPen strengths aur US label ka schedule
India mein Mounjaro KwikPen in strengths mein milta hai: 2.5, 5, 7.5, 10, 12.5 aur 15 mg6. Har pen mein 4 weekly doses hoti hain, isliye ek pen aam taur par ek mahina chalta hai6. Single-dose vial 2.5 mg aur 5 mg mein milti hai6.
Schedule Indian pack se nahi, US labels se aata hai. US Mounjaro label tirzepatide ko 2.5 mg hafte mein ek baar se shuru karta hai12. US Zepbound label (tirzepatide ka US wajan brand) 2.5 mg ko 4 hafte rakhta hai, phir dose 2.5 mg ke steps mein badhti hai3. Wajan ke liye is label ki maintenance dose 5, 10 ya 15 mg hafte mein ek baar hai3. Sabhi upyogon ke liye maximum dose 15 mg hafte mein ek baar hai3. Yeh US label ke schedule hain, aur aapki dose aapke doctor tay karte hain.
Agar ek dose chhoot jaye, to US Mounjaro label kehta hai ki use 4 din (96 ghante) ke andar jaldi se jaldi lein12. Label ke mutabik 4 din se zyada beet jayein to woh dose chhod dein, aur agli dose usual din par lein12. Storage ke niyam aap Mounjaro in India par dekh sakte hain.
Side effects, emergency mein 112 aur kab turant doctor se milein
US Zepbound label ke wajan wale trials mein har dose par 56 % logon ko pet se juda koi side effect hua, placebo par 30 % ko3. Nausea (ji machlana) 25 se 29 % logon ko hua, placebo par 8 % ko3. Dast 19 se 23 %, ulti 8 se 13 % aur kabz 11 se 17 % mein hui3. Placebo par yeh 8, 2 aur 5 % thi3. US label ke mutabik zyadatar nausea, ulti aur dast dose badhne ke dauran hue aur samay ke saath kam hue3. NHS kehti hai ki side effects pareshan karein ya na jayein to salah lein, aur jab tak mana na kiya jaye dawa lete rahein4.
Emergency. India ka emergency number 112 hai15.
- Gala ya jeebh suj jaye, khujli ke saath ubhra rash nikle, ya saans lene mein mushkil ho. NHS ke mutabik yeh serious allergic reaction ho sakta hai4. Turant 112 par call karein15.
- Agar kisi ko bahut low blood sugar ho sakta hai aur woh normal jawab nahi de raha ya behosh hai, to turant 112 par call karein15,16.
- Behosh vyakti ko kuch khane ya peene ko na dein16.
Turant doctor se sampark karein:
- Pet mein tez dard jo theek na ho, chahe ulti ho ya na ho. Zepbound ki US Medication Guide kehti hai ki dawa band karein aur turant doctor ko call karein3. NHS ke ek leaflet ke mutabik yeh pancreas ki sujan ka sign ho sakta hai11.
- Pet ke upar dard, bukhar, peeli skin ya aankhein, ya mitti jaise rang ka stool. US Medication Guide inhe gallbladder ki problem ke sign batati hai3. Turant doctor se sampark karein3.
- Pet ruka hua lage, ya bahut zyada kabz ho. US Zepbound label approval ke baad ki reports mein aant ruk jane (ileus) aur intestinal obstruction ki baat karta hai3. India sarkar bowel obstruction ko severe side effect maanti hai14. Turant medical madad lein.
Low blood sugar: turant ilaaj karein, phir doctor ko batayein.
- Insulin ya sulfonylurea bhi le rahe hon, to US label ke mutabik tirzepatide low blood sugar ka risk badha sakta hai, severe low blood sugar ka bhi3. NHS ke mutabik iske sign pasina, tez dhadkan, chakkar ya confusion ho sakte hain4.
- NHS ki salah hai ki diabetes wala vyakti ise jaldi theek kare, jaise ek chhota glass fruit juice peekar16. Phir doctor ko batayein.
Usi din doctor se sampark karein:
- Itni ulti ki koi bhi liquid pet mein na ruke, ya dast mein khoon aaye. Usi din doctor se sampark karein17.
Doctor ko batayein:
- US label ki boxed warning kehti hai ki tirzepatide se rats mein thyroid C-cell tumour hue; insaanon mein aisa hota hai ya nahi, yeh pata nahi3. Gardan mein ganth, nigalne mein dikkat, saans phoolna ya bhaari awaaz jo theek na ho, to doctor ko batayein3.
Kisi bhi side effect ke shak par doctor ko batayein. Aap khud bhi India ke Pharmacovigilance Programme (PvPI) ko report kar sakte hain: helpline 1800 180 3024, sirf working days18,19. Dose ke hisaab se har rate Mounjaro side effects page par hai.
Kaun Mounjaro na le: US label, NHS aur India ki shart
India mein Mounjaro sirf prescription par milta hai, isliye doctor ko apni puri health history batayein6.
- Thyroid cancer: US label ke mutabik jinki personal ya family history mein medullary thyroid cancer hai, ya jinhe MEN 2 hai, unhe tirzepatide nahi lena chahiye3.
- Allergy ya pancreatitis: NHS kehti hai ki tirzepatide shayad un logon ko suit na kare jinhe GLP-1 dawa se allergy hui ho4. Yahi baat un par bhi lagti hai jinhe acute pancreatitis hai ya pehle hua tha4.
- Severe gastroparesis: US label pet ke bahut dheere khali hone ki is bimari mein tirzepatide ki salah nahi deta3.
- Pregnancy aur breastfeeding: NHS ke mutabik pregnancy mein tirzepatide nahi diya jata; pregnancy hone par doctor ko bata dein4. Breastfeeding mein bhi ise use nahi kiya jata, kyonki pata nahi ki yeh doodh mein jata hai ya nahi4.
- Surgery: US label ke mutabik general anaesthesia ya deep sedation ke dauran pet ki cheezein lungs mein ja sakti hain3. Isliye planned surgery ya procedure se pehle doctor ko batayein ki aap tirzepatide le rahe hain3.
- Contraceptive pill: US label ke mutabik tirzepatide pill ka asar kam kar sakta hai3. Label non-oral tarika, ya shuru karne aur har dose badhne ke baad 4 hafte tak barrier method ki salah deta hai3.
Wajan kam karne ke injection: India mein kaun se hain
Hamare sources mein India ke wajan wale prescription injection tirzepatide (Mounjaro, Yurpeak) aur semaglutide ke hain5,8,9,20. Novo Nordisk ka Wegovy, yaani semaglutide 2.4 mg, India mein 24 June 2025 ko launch hua21. CDSCO ki committee ke records ke mutabik Wegovy adults mein chronic weight management ke liye approved hai20. Poviztra Wegovy ka doosra brand hai, jise Emcure bechta hai22. Iska reported upyog bhi adults mein chronic weight management hai23.
Ozempic India mein type 2 diabetes ke liye hai24. Semaglutide ka patent India mein 20 March 2026 ko khatam hua, aur generic brands aaye25. Jo CDSCO minutes humne padhe, unmein zyadatar generic approvals type 2 diabetes ke liye hain, aur kuch brands wajan ke liye bhi report hue hain26. PharmEasy ke mutabik India mein har semaglutide brand Schedule H prescription dawa hai27.
Hamare sources mein koi ek injection sabke liye sabse achha nahi bataya gaya. Dawa, brand aur dose aapke doctor tay karte hain. PharmEasy ke mutabik 2026 mein India mein nakli GLP-1 pens report hue hain28. Sarkar ki salah hai ki pehle qualified specialist se milein, aur yeh dawaein sirf prescription par, regulated channels se lein14. Saare brand GLP-1 medicines in India page par hain, aur semaglutide injection Hinglish mein semaglutide injection ke upyog page par.
India mein Mounjaro ki keemat: PharmEasy MRP, 1 October 2026
Aksar puchhe jaane wale sawal (FAQ)
Mounjaro injection kya hai? Yeh Eli Lilly ka tirzepatide brand hai: hafte mein ek baar ka prescription injection1,2. US label ke mutabik yeh GIP aur GLP-1 receptors ko activate karta hai3.
Mounjaro injection ka upyog kis liye hota hai? India mein iska upyog type 2 diabetes aur weight management hai5. Weight management BMI 30 ya zyada, ya 27 ya zyada ke saath wajan se judi bimari wale adults ke liye hai5.
Kya Mounjaro India mein milta hai? Haan, India mein Mounjaro 20 March 2025 se doctor ke prescription par milta hai1,6.
Mounjaro ke kya side effects hain? US label ke trials mein sabse aam side effects mein nausea, dast, ulti aur kabz the3. Gala sujne ya saans mein dikkat par turant 112 par call karein4,15.
Tezi se wajan ghatane ke liye sabse achhi dawa kaun si hai? Hamare sources mein koi ek dawa sabke liye sabse achhi nahi bataai gayi. Yeh page wajan ki speed ka koi vaada nahi karta. Doctor aapki health dekhkar dawa aur dose tay karte hain. CDSCO ne 10 March 2026 ko manufacturers ko GLP-1 weight-loss dawaon ke surrogate ads aur aise indirect promotion se mana kiya jo logon ko gumraah kar sake29.
Tirzepatide ya koi aur dawa aapke liye theek hai ya nahi, yeh jaanne ke liye Zelta ke doctor se consultation book karein.
Sources
- ThePrint, 2025-03-20
- BioSpectrum India (Lilly India release), 2025-08-15
- Zepbound US label (DailyMed, 2026-08-28)
- NHS medicines guide: tirzepatide
- The Week / PTI, 2025-03-20
- PharmEasy, updated 2026-10-01 (pharmacy listing)
- Bloomberg via Yahoo, 2026-04-09
- BioVoice, 2025-12-11
- Cipla NSE filing with press release 'Lilly and Cipla sign a distribution and promotion agreement for Yurpeak (tirzepatide) in India', 2025-10-23
- PharmEasy, 'Yurpeak price in India: MRP and monthly cost', updated 2026-10-01 (read 2026-10-29) (pharmacy listing)
- Leeds Community Healthcare NHS Trust, diabetes patient leaflet 'GLP-1 or GIP diabetes treatment' (page dated 2026-04-30)
- Mounjaro US label (DailyMed, 2026-08-27)
- CDSCO SEC (Endocrinology & Metabolism) minutes, 2026-06-24
- PIB backgrounder 'GLP-1 Drugs: Use, Risks, and Regulation', 2026-04-01
- Government of Meghalaya, DIPR press release, 2026-05-27
- NHS, 'Low blood sugar (hypoglycaemia)' (read 2026-10-21)
- NHS, 'Diarrhoea and vomiting' (page last reviewed 2023-12-21)
- Indian Pharmacopoeia Commission, PvPI page (undated, read 2026-10-21)
- Indian Pharmacopoeia Commission, PvPI FAQ (undated, read 2026-10-21)
- CDSCO SEC (Endocrinology & Metabolism) minutes, 2026-04-23
- Business Today, 2025-06-24
- BioSpectrum India, 2025-11-10
- Indian Pharma Post, 'Emcure Pharma launches weight loss drug Poviztra in India', 2025-12-22
- Storyboard18, 2025-12-15 (Novo Nordisk India MD to CNBC-TV18)
- CareEdge, 2026-03-10
- CDSCO SEC minutes and press reports
- PharmEasy, updated 2026-10-01 (pharmacy listing)
- PharmEasy, 'Wegovy (semaglutide) in India', updated 2026-10-01 (read 2026-10-29) (pharmacy listing)
- Ministry of Health and Family Welfare press release via PIB, 2026-03-24
Medical Disclaimer
This article is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. The clinical trial results cited in this article reflect study averages from specific trial populations and may not predict individual outcomes. Drug availability, approved indications, and brand names vary by country and are subject to regulatory decisions by bodies such as the CDSCO in India, the FDA in the United States, and the EMA in Europe. Zelta does not endorse one medication over another. All treatment decisions are made by your prescribing clinician based on your individual health profile.